Anti-Müllerian Hormone, Inhibin B, and Antral Follicle Count in Young Women with Ovarian Failure
Open accessThe DOI matches its Crossref record.
Abstract
CONTEXT: Ovarian dysfunction is classically categorized on the basis of cycle history, FSH, and estradiol levels. Novel ovarian markers may provide a more direct insight into follicular quantity in hypergonadotropic women. OBJECTIVE: The objective of the study was to investigate the distribution of novel ovarian markers in young hypergonadotropic women as compared with normogonadotropic regularly menstruating women. DESIGN: This was a nationwide prospective cohort study. SETTING: The study was conducted at 10 hospitals in The Netherlands. PATIENTS: Women below age 40 yr with regular menses and normal FSH (controls; n = 83), regular menstrual cycles and elevated FSH [incipient ovarian failure (IOF); n = 68]; oligomenorrhea and elevated FSH [referred to as transitional ovarian failure (TOF); n = 79]; or at least 4 months amenorrhea together with FSH levels exceeding 40 IU/liter [premature ovarian failure (POF); n = 112]. MAIN OUTCOME MEASURES: Serum levels of anti-Müllerian hormone (AMH), inhibin B, and antral follicle count (AFC) was measured. RESULTS: All POF patients showed AMH levels below the fifth percentile (p(5)) of normoovulatory women. Normal AMH levels (>p(5)) could be identified in 75% of IOF, 33% of TOF patients, and 98% of controls. AFC and AMH levels changed with increasing age (P < 0.0001), whereas inhibin B did not (P = 0.26). AMH levels were significantly different between TOF and IOF over the entire age range, whereas AFC became similar for TOF and IOF at higher ages. CONCLUSIONS: Compared with inhibin B and AFC, AMH was more consistently correlated with the clinical degree of follicle pool depletion in young women presenting with elevated FSH levels. AMH may provide a more accurate assessment of the follicle pool in young hypergonadotropic patients, especially in the clinically challenging subgroups of patients with elevated FSH and regular menses (i.e. IOF) and in hypergonadotropic women with cycle disturbances not fulfilling the POF diagnostic criteria (i.e. TOF).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012) · Menopause · doi:10.1097/gme.0b013e31824d8f40 · Cited by 1,705
Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., de Villiers, T. J., & for the STRAW + 10 Collaborative Group (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3362 · Cited by 1,325
Ovarian aging: mechanisms and clinical consequences
Broekmans, F. J., Soules, M. R., & Fauser, B. C. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0006 · Cited by 1,248
Self-citationHuman ovarian reserve from conception to the menopause
Wallace, W., & Kelsey, T. (2009) · Nature Precedings · doi:10.1038/npre.2009.3179.1 · Cited by 878
Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., de Villiers, T. J., & for the Straw +10 Collaborative Group (2012) · Climacteric · doi:10.3109/13697137.2011.650656 · Cited by 817
De Vos, M., Devroey, P., & Fauser, B. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60355-8 · Cited by 763
Self-citationAnti-Müllerian hormone: ovarian reserve testing and its potential clinical implications
Broer, S. L., Broekmans, F. J. M., Laven, J. S. E., & Fauser, B. C. J. M. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu020 · Cited by 683
Self-citationDewailly, D., Lujan, M. E., Carmina, E., Cedars, M. I., Laven, J., Norman, R. J., & Escobar-Morreale, H. F. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt061 · Cited by 551
Self-citationA Validated Model of Serum Anti-Müllerian Hormone from Conception to Menopause
Kelsey, T. W., Wright, P., Nelson, S. M., Anderson, R. A., & Wallace, W. H. B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022024 · Cited by 457
Hagen, C. P., Aksglaede, L., Sørensen, K., Main, K. M., Boas, M., Cleemann, L., Holm, K., Gravholt, C. H., Andersson, A.-M., Pedersen, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0930 · Cited by 383
Chemotherapy-Induced Damage to Ovary: Mechanisms and Clinical Impact
Bedoschi, G., Navarro, P. A., & Oktay, K. (2016) · Future Oncology · doi:10.2217/fon-2016-0176 · Cited by 356
Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency
Visser, J. A., Schipper, I., Laven, J. S. E., & Themmen, A. P. N. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.224 · Cited by 264
Self-citationLunding, S. A., Aksglaede, L., Anderson, R. A., Main, K. M., Juul, A., Hagen, C. P., & Pedersen, A. T. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1621 · Cited by 125
“AMH was higher in TS patients with mosaicism (45,X/ 46,XX) compared with patients with 45,X (16 pmol/L [ 2–92] vs 2 pmol/L [ 2–2]; P .”
BackgroundFalorni, A., Brozzetti, A., Aglietti, M. C., Esposito, R., Minarelli, V., Morelli, S., Sbroma Tomaro, E., & Marzotti, S. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04387.x · Cited by 25
Metadata
- Authors
- Knauff, E. A. H., Eijkemans, M. J. C., Lambalk, C. B., ten Kate-Booij, M. J., Hoek, A., Beerendonk, C. C. M., Laven, J. S. E., Goverde, A. J., Broekmans, F. J. M., Themmen, A. P. N., de Jong, F. H., Fauser, B. C. J. M., & on behalf of the Dutch Premature Ovarian Failure Consortium
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-03-01
- Volume
- 94
- Issue
- 3
- Pages
- 786-792
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2105725429
- Cited by
- 232
- References
- 0
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.